{"prompt": "['CONFIDENTIAL', 'Verrica Pharmaceuticals Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', '6.1.4', 'Refusal of Investigational Product Administration', 'Any subject refusing clinical trial material for any reason will be discontinued from the', 'study, and the reason(s) will be documented on the appropriate CRF page. Reasonable', 'efforts should be made to monitor the subject for AEs and to complete follow-up', 'assessments after treatment discontinuation. These efforts should be documented on', 'the appropriate CRF page.', '6.1.5', 'Withdrawal of Consent', 'Any subject who withdraws consent for any reason at any time during the study will be', 'discontinued from the study, and the reason(s) will be documented on the appropriate', 'CRF page. If subjects do not want their data that has already been submitted or', 'specimens utilized they will need to submit a request in writing to the Investigator for', 'removal of their information.', '6.2', 'PREMATURE STUDY OR SITE TERMINATION', 'If the Sponsor, investigator, medical monitor, study monitor, or appropriate regulatory', 'officials discover conditions arising during the study that indicate that the study should', 'be halted or that the site should be terminated, this action may be taken after appropriate', 'consultation among the Sponsor, investigator, medical monitor, and study monitor.', 'Conditions that may warrant termination of the study include, but are not limited to,', 'the following:', 'The discovery of an unexpected, serious, or unacceptable risk to the subjects', 'enrolled in the study', 'A decision on the part of the Sponsor to suspend or discontinue testing, evaluation,', 'or development of the product', 'A study conducted at a single site in a multicenter study may also warrant termination', 'under the following conditions:', 'Failure of the investigator to enroll subjects into the study at an acceptable rate', 'Page 55']['CONFIDENTIAL', 'Verrica Pharmaceuticals Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', 'Failure of the investigator to comply with pertinent regulations of appropriate', 'regulatory authorities', 'Submission of knowingly false information from the site to the sponsor, study', 'monitor, or appropriate regulatory authority', 'Insufficient adherence to protocol requirements', 'Study termination and follow-up will comply with the conditions set forth in', 'International Council for Harmonisation E6, Guideline for Good Clinical Practice.', 'Page 56']['CONFIDENTIAL', 'Verrica Pharmaceuticals Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', '7.0', 'DATA COLLECTION AND PROCESSING AND STATISTICAL ANALYSIS', '7.1', 'DATA COLLECTION AND PROCESSING', \"Hard copy/paper CRF's will be used to capture study assessments and data. The\", 'investigator is required to prepare and maintain adequate and accurate source', 'documents designed to record all observations and other data pertinent to the study for', 'each study subject. The study coordinator or other delegated study personnel will enter', 'data from source documents into the CRFs. A combination of both is also acceptable.', 'All CRFs will be reviewed and source-verified by the study monitor centrally and', 'during periodic site visits, and the study monitor will ensure that all data in the CRF', 'are correct and complete. All information recorded on the CRFs for this study must be', 'consistent with the source documentation (i.e., medical records). Before or between', 'visits, the medical monitor or study monitor may conduct a preliminary medical review', 'of the CRFs. Once the CRFs are completed and source-verified, the investigator must', 'sign all required pages in the CRF, verifying the accuracy of all data contained in the', 'CRF.', 'Training will be provided for CRF completion at the study initiation visit. All study', 'personnel completing the forms must have the necessary education, training, and', 'experience or any combination of these. The investigator will be responsible for', 'documenting employee education, training, and previous experience for those assigned', 'to support the required study activities.', 'If electronic data systems are used for documentation and data capture, the investigator', 'must ensure that the systems are validated and that data are backed up as described in', 'Section 7.4.', 'Page 57']\n\n###\n\n", "completion": "END"}